应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
ZLAB 再鼎医药
交易中 09-10 10:52:02 EDT
24.23
-0.85
-3.39%
最高
24.33
最低
23.64
成交量
33.44万
今开
24.01
昨收
25.08
日振幅
2.75%
总市值
27.22亿
流通市值
23.53亿
总股本
1.12亿
成交额
805.06万
换手率
0.34%
流通股本
9,711万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
纳斯达克中国金龙指数跌超0.5%,再鼎医药跌5.03%,金山云跌4.26%,禾赛科技跌3.17%,晶科能源跌3.04%,
智通财经 · 21:30
纳斯达克中国金龙指数跌超0.5%,再鼎医药跌5.03%,金山云跌4.26%,禾赛科技跌3.17%,晶科能源跌3.04%,
纳斯达克中国金龙指数涨超0.5%,巨龙在线涨22.78%,再鼎医药涨7.19%,NXTT涨6.77%,信也科技涨3.61
智通财经 · 09-02
纳斯达克中国金龙指数涨超0.5%,巨龙在线涨22.78%,再鼎医药涨7.19%,NXTT涨6.77%,信也科技涨3.61
美股异动 | 再鼎医药涨逾7%,DLL3 ADC启动一线SCLC全球三期临床
智通财经 · 09-02
美股异动 | 再鼎医药涨逾7%,DLL3 ADC启动一线SCLC全球三期临床
美股异动 | 再鼎医药(ZLAB.US)涨逾8% DLL3 ADC启动一线SCLC全球三期临床
智通财经 · 09-02
美股异动 | 再鼎医药(ZLAB.US)涨逾8% DLL3 ADC启动一线SCLC全球三期临床
再鼎医药早盘涨逾6% DLL3 ADC启动一线SCLC全球三期临床
新浪港股 · 09-02
再鼎医药早盘涨逾6% DLL3 ADC启动一线SCLC全球三期临床
再鼎医药(ZLAB)盘中震荡走软跌4.43% 中期归属于上市公司股东净亏损同比扩大14%
金吾财讯 · 08-31
再鼎医药(ZLAB)盘中震荡走软跌4.43% 中期归属于上市公司股东净亏损同比扩大14%
纳斯达克中国金龙指数跌超0.5%,乐信跌13.14%,小马智行跌4.75%,贝壳跌2.70%,再鼎医药跌2.03%,阿里
智通财经 · 08-31
纳斯达克中国金龙指数跌超0.5%,乐信跌13.14%,小马智行跌4.75%,贝壳跌2.70%,再鼎医药跌2.03%,阿里
再鼎医药:上半年净亏损1.02亿美元 同比扩大14%
财中社 · 08-26
再鼎医药:上半年净亏损1.02亿美元 同比扩大14%
再鼎医药(09688)中期亏损净额同比增长14.22% 产品收入净额减少6.25%
金吾财讯 · 08-26
再鼎医药(09688)中期亏损净额同比增长14.22% 产品收入净额减少6.25%
【券商聚焦】国泰海通维持再鼎医药(09688)增持 指增长动能切换至新药
金吾财讯 · 08-25
【券商聚焦】国泰海通维持再鼎医药(09688)增持 指增长动能切换至新药
纳斯达克中国金龙指数涨超0.5%,金山云涨10.44%,再鼎医药涨6.59%,金生游乐涨6.30%,世纪互联涨4.56%
智通财经 · 08-19
纳斯达克中国金龙指数涨超0.5%,金山云涨10.44%,再鼎医药涨6.59%,金生游乐涨6.30%,世纪互联涨4.56%
港股异动 | 再鼎医药(09688)早盘涨近7% argenx FcRn靶向药3期成功 再鼎拥有大中华区权益
智通财经 · 08-19
港股异动 | 再鼎医药(09688)早盘涨近7% argenx FcRn靶向药3期成功 再鼎拥有大中华区权益
纳斯达克中国金龙指数跌超1%,中进医疗跌15.44%,网易跌4.33%,再鼎医药跌2.46%,新东方跌3.37%,中通跌
智通财经 · 08-12
纳斯达克中国金龙指数跌超1%,中进医疗跌15.44%,网易跌4.33%,再鼎医药跌2.46%,新东方跌3.37%,中通跌
再鼎医药午前涨超5% 公司自主研发资产正逐步进入临床价值验证阶段
新浪港股 · 08-12
再鼎医药午前涨超5% 公司自主研发资产正逐步进入临床价值验证阶段
港股开盘 | 恒指低开0.6% 黄金股走强 再鼎医药(09688)涨超8%
智通财经 · 08-12
港股开盘 | 恒指低开0.6% 黄金股走强 再鼎医药(09688)涨超8%
港股开盘|港股开盘持平;医药股走强;再鼎医药涨超8%
港股开盘 · 08-12
港股开盘|港股开盘持平;医药股走强;再鼎医药涨超8%
再鼎医药(09688)授出购股权及受限制股份单位
智通财经 · 08-11
再鼎医药(09688)授出购股权及受限制股份单位
港股午评|恒生指数早盘跌0.63% CRO概念继续走高
智通财经 · 08-11
港股午评|恒生指数早盘跌0.63% CRO概念继续走高
港股异动 | 再鼎医药(09688)涨超7% Q2产品收入环比增长11% 花旗看好中国业务下半年企稳
智通财经 · 08-11
港股异动 | 再鼎医药(09688)涨超7% Q2产品收入环比增长11% 花旗看好中国业务下半年企稳
快讯:恒指高开0.24% 科指涨0.27% 黄金股普涨 AI应用股活跃
新浪港股 · 08-11
快讯:恒指高开0.24% 科指涨0.27% 黄金股普涨 AI应用股活跃
公司概况
公司名称:
再鼎医药
所属市场:
NASDAQ
上市日期:
--
主营业务:
再鼎医药有限公司是一家主要从事生物制药业务的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物,其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。该公司在国内市场和海外市场开展业务。
发行价格:
--
{"stockData":{"symbol":"ZLAB","market":"US","secType":"STK","nameCN":"再鼎医药","latestPrice":24.23,"timestamp":1789051919687,"preClose":25.08,"halted":0,"volume":334437,"delay":0,"changeRate":-0.0338915470494417,"floatShares":97110400,"shares":112353700,"eps":-1.702952,"marketStatus":"交易中","change":-0.85,"latestTime":"09-10 10:52:02 EDT","open":24.01,"high":24.33,"low":23.64,"amount":8050613.616305999,"amplitude":0.027512,"askPrice":24.24,"askSize":200,"bidPrice":24.21,"bidSize":111,"shortable":3,"etf":0,"ttmEps":-1.702952,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1789070400000},"marketStatusCode":2,"adr":1,"adrRate":10,"listingDate":1505880000000,"exchange":"NASDAQ","adjPreClose":25.08,"preHourTrading":{"tag":"盘前","latestPrice":24,"preClose":25.08,"latestTime":"09:29 EDT","volume":4559,"amount":110795.407512,"timestamp":1789046999016,"change":-1.08,"changeRate":-0.043062,"amplitude":0.029107},"postHourTrading":{"tag":"盘后","latestPrice":25.08,"preClose":25.08,"latestTime":"19:30 EDT","volume":6526,"amount":163672.07,"timestamp":1788996607182,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.147507,"impliedVol":0.5619,"impliedVolPercentile":0.3586},"requestUrl":"/m/hq/s/ZLAB/wiki","defaultTab":"wiki","newsList":[{"id":"2666998175","title":"纳斯达克中国金龙指数跌超0.5%,再鼎医药跌5.03%,金山云跌4.26%,禾赛科技跌3.17%,晶科能源跌3.04%,","url":"https://stock-news.laohu8.com/highlight/detail?id=2666998175","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666998175?lang=zh_cn&edition=full","pubTime":"2026-09-10 21:30","pubTimestamp":1789047045,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4548","02525","BK4139","BK4563","BK4124","LU2476274720.SGD","09688","BK4585","ZLAB","BK4588","ACES","BK4526","BK4141","BK4531","BK4607","BK4608","LU2778985437.USD","JKS","LU2476274308.USD","BK4519","BK4116","HSAI","KC","LU2488822045.USD","03896","HXC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664120018","title":"纳斯达克中国金龙指数涨超0.5%,巨龙在线涨22.78%,再鼎医药涨7.19%,NXTT涨6.77%,信也科技涨3.61","url":"https://stock-news.laohu8.com/highlight/detail?id=2664120018","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664120018?lang=zh_cn&edition=full","pubTime":"2026-09-02 22:01","pubTimestamp":1788357697,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2488822045.USD","JLHL",".HXC","NXTT","ZLAB","BK4531","BK4129","BK4588","BK4585","FINV","BK4023","BK4526","BK4548","BK4139","BK4166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664122038","title":"美股异动 | 再鼎医药涨逾7%,DLL3 ADC启动一线SCLC全球三期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2664122038","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664122038?lang=zh_cn&edition=full","pubTime":"2026-09-02 21:58","pubTimestamp":1788357538,"startTime":"0","endTime":"0","summary":"消息面上,8月31日,$再鼎医药$在Clinicaltrials.gov网站上注册了ZL-1310+PD-L1抗体一线治疗ES-SCLC的全球三期临床试验。该全球三期临床拟入组530例一线ES-SCLC患者,预计2030年6月初步完成。ZL-1310为一款靶向DLL3的ADC新药,采用宜联新一代ADC技术TMALIN构建,以TOPO1抑制剂作为payload,具有高效力、高清除率和高渗透性的作用特点。ZL-1310在小细胞肺癌PDX模型的临床前研究中显示出强效杀伤作用。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491227.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再鼎医药DLL3 ADC启动一线SCLC全球三期临床","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4548","BK1588","BK4526","09688","BK4531","BK1574","BK4588","ZLAB","LU2488822045.USD","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664812769","title":"美股异动 | 再鼎医药(ZLAB.US)涨逾8% DLL3 ADC启动一线SCLC全球三期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2664812769","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664812769?lang=zh_cn&edition=full","pubTime":"2026-09-02 21:50","pubTimestamp":1788357014,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","ZLAB","BK4548","BK4588","BK4139","BK4531","BK4526","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664898546","title":"再鼎医药早盘涨逾6% DLL3 ADC启动一线SCLC全球三期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2664898546","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664898546?lang=zh_cn&edition=full","pubTime":"2026-09-02 10:16","pubTimestamp":1788315360,"startTime":"0","endTime":"0","summary":"模拟交易客户端再鼎医药早盘涨逾6%。截至发稿,股价上涨5.97%,现报20.60港元,成交额5967.91万港元。8月31日,再鼎医药在Clinicaltrials.gov网站上注册了ZL-1310+PD-L1抗体一线治疗ES-SCLC的全球三期临床试验。该全球三期临床拟入组530例一线ES-SCLC患者,预计2030年6月初步完成。2026 年下半年重要催化剂包括:Zoci一线小细胞肺癌联合治疗数据公布、1L SCLC 及肺外神经内分泌癌注册性开发推进;ZL-1503首次人体数据公布等。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-02/doc-iniqkzme7832199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4531","BK4588","BK1161","09688","BK4526","BK1588","LU2488822045.USD","ZLAB","BK4548","BK1574","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663049960","title":"再鼎医药(ZLAB)盘中震荡走软跌4.43% 中期归属于上市公司股东净亏损同比扩大14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663049960","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663049960?lang=zh_cn&edition=full","pubTime":"2026-08-31 23:02","pubTimestamp":1788188527,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药(ZLAB)盘中震荡走软,截至发稿,最新报24.93美元,下跌4.43%,成交额621.24万美元。消息面上,再鼎医药新近披露2026年中期财报,年初至报告期末实现营业收入2.06亿美元,同比下降5%;归属于上市公司股东的净亏损为1.02亿美元,同比扩大14%。截至2026年6月30日,公司资产合计10.75亿美元,负债合计4.68亿美元,基本及摊薄每股亏损为0.09美元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/N2NlYWIzMDQ5MjY5YzU0NWM0NDMwZTE4ZDQ3MjY3ODIxNTA5MDg=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/N2NlYWIzMDQ5MjY5YzU0NWM0NDMwZTE4ZDQ3MjY3ODIxNTA5MDg=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305520","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2488822045.USD","BK4526","BK1588","BK4531","BK4548","BK4585","BK1574","BK4588","ZLAB","09688","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663988006","title":"纳斯达克中国金龙指数跌超0.5%,乐信跌13.14%,小马智行跌4.75%,贝壳跌2.70%,再鼎医药跌2.03%,阿里","url":"https://stock-news.laohu8.com/highlight/detail?id=2663988006","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663988006?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:30","pubTimestamp":1788183025,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0348814723.USD","LU1282648689.USD","BK4122","BABC","09988","BK4535","LU2148611432.USD","BK4503","BK4565","ALBmain","BEKE","BK4581","BK4558","LU0047713382.USD","LU0244354667.USD","LU0287142896.SGD","BABU","LU1048588211.SGD","LU1152091168.USD","BK4579","LU0049112450.USD","LU0979878070.USD","BK4220","LU1831875114.USD","LU0738911758.USD","LU0545039389.USD","LU0359202008.SGD","BK4139","02423","BK4526","BK4504","LU0501845795.SGD","LU0067412154.USD","LU1267930227.SGD","02026","BK4079","BK4588","LU0661504455.SGD","LU1051768304.USD","BK4585","LU0651946864.USD","BK4527","LU2488822045.USD","LU0918141705.HKD","BK4502","LU0326950275.SGD","IE00BF5LJ272.USD","BK4166","09688","LU1105468828.SGD","LU1046422090.SGD","DRAG","LU1880383366.USD","LU1769817179.HKD","ZLAB","BABO","LU1048596156.SGD","KBAB","LU0072462343.USD","BK4554","LU1688375341.USD","BK4505","BK4533","BK4023","LU1003077747.HKD","LU0456842615.SGD","BK4614","LU0463099449.HKD","LU0128525689.USD","LX","LU2226246903.HKD","BK4531","LU0348816934.USD","BK4509","LU0821914370.USD","LU1023057109.AUD","LU1242518857.USD","LU1046421795.USD","LU1823568750.SGD","BBYY","BABW","BK4548","LU0072913022.USD","BK4607","ONLN","LU1051769294.HKD","BK4524","LU0359201885.HKD","LU1188198961.HKD","LU1515016050.SGD","LU1008478684.HKD","BK4575","PONX","BABA","IE00B0JY6N72.USD","BK4534","LU1235294995.USD","LU0328353924.USD","LU0251143458.SGD","LU0918141887.USD","IE00BFMHRM44.USD","LU1242518931.SGD","BK4543","BK4538","BK4587","LU0052756011.USD","LU0797268264.HKD","LU0310800965.SGD","PONY","LU0106959298.USD","LU1152091754.HKD","HXC","LU1769817096.USD","LU0651947912.USD","LU0553294199.USD","LU0949170772.SGD","LU1235295612.USD","BABX","LU0359201612.USD","LU0173614495.USD","LU0880133367.SGD","CLIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662695887","title":"再鼎医药:上半年净亏损1.02亿美元 同比扩大14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662695887","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662695887?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:22","pubTimestamp":1787707320,"startTime":"0","endTime":"0","summary":"8月26日,再鼎医药(09688/ZLAB)发布2026年中期业绩,公司产品收入净额为2.01亿美元,同比下降6%,主要由于则乐的收入下降(受奥拉帕利仿制药入围集中采购影响)及卫伟迦的收入下降(与国家医保目录续约相关的价格调整)。这些下降部分被鼎优乐的销售额增长(受益于强劲的患者需求和医院覆盖范围的持续扩大)及纽再乐的销售额增长所抵销。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608263854197972.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608263854197972.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","LU2488822045.USD","BK4531","BK1161","ZLAB","BK1574","BK4588","BK1588","BK4548","BK4526","09688","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662765771","title":"再鼎医药(09688)中期亏损净额同比增长14.22% 产品收入净额减少6.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662765771","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662765771?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:01","pubTimestamp":1787706074,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药(09688)公布截至2026年6月30日止六个月的中期业绩,亏损净额1.02亿美元,同比增长14.22%,主要由于许可费的增加。每股基本亏损0.09美元。董事会未建议就2025年及2026年上半年派发任何中期股息。期内,实现总营收2.06亿美元,同比减少4.87%。其中,产品收入净额为2.01亿美元,同比减少6.25%,主要由于则乐的收入下降(由于奥拉帕利仿制药入围集中采购导致医院用药模式发生改变)以及卫伟迦的收入下降(主要是由于与国家医保目录续约相关的价格调整)。期内研发开支增加14%至1.27亿美元,主要由于公司的许可和合作协议项下许可费的增加。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MTU2NzYxOTI1Mjg5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MTU2NzYxOTI1Mjg5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989411","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","ZLAB","09688","BK4531","BK1574","BK4588","BK4585","BK4526","BK4548","BK1588","BK4139","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662781278","title":"【券商聚焦】国泰海通维持再鼎医药(09688)增持 指增长动能切换至新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2662781278","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662781278?lang=zh_cn&edition=full","pubTime":"2026-08-25 15:15","pubTimestamp":1787642144,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国泰海通证券发布研报指,再鼎医药 产品收入边际改善,增长动能切换至新药,核心关注Zoci注册临床推进及ZL-1503的FIH数据。2026年上半年公司总收入2.06亿美元,同比下降5%;产品收入净额2.01亿美元,同比下降6%。2026年上半年研发费用1.27亿美元,主因许可及合作协议授权费增加;销售及管理费用1.38亿美元(+3%),基本持平。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/ODYzMTA4NTI1Nzg5MjIw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODYzMTA4NTI1Nzg5MjIw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989297","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK0028","BK0184","BK0276","BK1588","BK1574","BK4585","KCE","BK4531","BK4588","BK0012","BK1161","LU2488822045.USD","09688","BK0188","601211","BK1564","BK0201","02611","ZLAB","BK0183","BK1147","BK4526","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660426681","title":"纳斯达克中国金龙指数涨超0.5%,金山云涨10.44%,再鼎医药涨6.59%,金生游乐涨6.30%,世纪互联涨4.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660426681","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660426681?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:40","pubTimestamp":1787146850,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4526","BK4531","BK4216","BK4116","BK4139","BK4563","BK4548","BK4588","BK4608","GDHG","VNET","ZLAB","LU1046422090.SGD","LU2488822045.USD","KC","BK4585","BK4535","BK4607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660419415","title":"港股异动 | 再鼎医药(09688)早盘涨近7% argenx FcRn靶向药3期成功 再鼎拥有大中华区权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2660419415","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660419415?lang=zh_cn&edition=full","pubTime":"2026-08-19 11:10","pubTimestamp":1787109029,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,再鼎医药(09688)早盘涨近7%,截至发稿,涨4.61%,报20.18港元,成交额1.31亿港元。消息面上,据药研网报道,8月17日,免疫学公司argenx宣布,核心产品FcRn拮抗剂(艾加莫德α)旗治疗成人自身免疫性肌炎的ALKIVIA 3期临床研究取得积极顶线结果。值得注意的是,argenx此前已将艾加莫德在大中华区的开发和商业化权益独家授予再鼎医药。值得注意的是,ALKIVIA研究本身是由argenx发起的3期全球研究,再鼎医药也参与了大中华区的临床开发和患者入组,若该适应症后续在全球获批,再鼎有望进一步拓展艾加莫德在中国自身免疫疾病领域的商业化版图。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4526","BK1161","BK4588","BK4531","BK1574","BK4139","LU2488822045.USD","09688","BK4548","KCAI","VXUS","BK1588","ZLAB","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908597","title":"纳斯达克中国金龙指数跌超1%,中进医疗跌15.44%,网易跌4.33%,再鼎医药跌2.46%,新东方跌3.37%,中通跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908597","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658908597?lang=zh_cn&edition=full","pubTime":"2026-08-12 21:30","pubTimestamp":1786541426,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1043141123.HKD","NERD","ZLAB","LU1228905540.USD","EDU","ESPO","LU0545562505.USD","LU0048580855.USD","ZJYL","LU1043141396.HKD","LU1807302812.USD","LU0502904849.HKD","LU1228905037.USD","BK4514","BK4503","BK4563","HERO","BK4510","LU0823426480.USD","LU1152091754.HKD","IE00BYV24P56.USD","BK4085","BK4204","LU0370786039.SGD","BK4509","BK4577","LU0359201612.USD","ODDS","BK4531","LU0823426308.USD","LU0327786744.USD","LU1880383366.USD","BK4082","LU0067412154.USD","LU1993786604.SGD","LU0880133367.SGD","BK4139","BK4505","LU1008478684.HKD","LU1152091168.USD","BK4588","IE00BVYPNQ40.USD","LU1880383440.USD","LU0426412945.USD","NTES","LU0426417589.USD","LU0994945656.USD","IE00BMCWC346.EUR","LU0072913022.USD","BK4501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658081928","title":"再鼎医药午前涨超5% 公司自主研发资产正逐步进入临床价值验证阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2658081928","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658081928?lang=zh_cn&edition=full","pubTime":"2026-08-12 11:45","pubTimestamp":1786506300,"startTime":"0","endTime":"0","summary":"模拟交易客户端再鼎医药早盘一度涨超11%,绩后股价已累涨超三成。截至发稿,股价上涨5.13%,现报19.48港元,成交额3.59亿港元。再鼎医药今年二季度实现总收入为1.063亿美元,产品收入净额为1.058亿美元,环比增长11%,得益于则乐的稳定表现以及艾加莫德的销量持续增长。中信建投指出,公司自主研发资产正逐步进入临床价值验证阶段,核心自研管线有望于年内迎来密集数据读出及关键研发进展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-12/doc-inimzqcr3698280.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1588","BK4531","LU2488822045.USD","BK4548","BK1161","BK4139","BK4526","BK1574","BK4588","ZLAB","BK4585","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658947545","title":"港股开盘 | 恒指低开0.6% 黄金股走强 再鼎医药(09688)涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658947545","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658947545?lang=zh_cn&edition=full","pubTime":"2026-08-12 09:29","pubTimestamp":1786498159,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,8月12日,恒生指数低开0.6%,报25498.39点;恒生科技指数跌0.8%,报4785.75点;国企指数跌0.57%,报8479.60点。大市盘前成交21.70亿港元。黄金股走强,紫金黄金国际涨超2%,中国黄金国际涨超2%,灵宝黄金涨超2%,老铺黄金涨近2%,山东黄金涨超1%。医药股走强,再鼎医药涨超8%,药明合联涨超1%。受再鼎医药隔夜美股涨超10%带动。受隔夜美股三大指数全线收跌、中概股金龙指数跌2.94%拖累,港股今日低开。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09688","BK1574","BK1161","LU2488822045.USD","BK1588","ZLAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168242546","title":"港股开盘|港股开盘持平;医药股走强;再鼎医药涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168242546","media":"港股开盘","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168242546?lang=zh_cn&edition=full","pubTime":"2026-08-12 09:21","pubTimestamp":1786497715,"startTime":"0","endTime":"0","summary":"盘面上,生物医药、资源金属及AI概念活跃,带动个股分化上行;在线娱乐、教育等消费服务类个股则出现回吐,市场风格短线偏向防御与结构性轮动。大型科技股延续弱势,多数回调逾0.5%,仅理想汽车小幅飘红;阿里、腾讯、京东等均低开,或受隔夜美股科技股走软及机构获利了结影响。盘面亮点集中在生物医药与资源股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","ZLAB","BK1588","BK4588","BK4531","159938","BK1161","BK4526","BK4139","09688","BK4548","BK4585","09939","KCAI","BK1515","BK1574","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658915078","title":"再鼎医药(09688)授出购股权及受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2658915078","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658915078?lang=zh_cn&edition=full","pubTime":"2026-08-11 21:56","pubTimestamp":1786456598,"startTime":"0","endTime":"0","summary":"智通财经APP讯,再鼎医药(09688)发布公告,本公司于授出日期根据2024年股权激励计划授出1000份(以美国存托股份计)购股权、2600股(以美国存托股份计)受限制股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","LU2488822045.USD","BK4531","BK4526","BK1588","BK4585","09688","BK4588","ZLAB","BK1574","BK1161","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658969219","title":"港股午评|恒生指数早盘跌0.63% CRO概念继续走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2658969219","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658969219?lang=zh_cn&edition=full","pubTime":"2026-08-11 12:00","pubTimestamp":1786420834,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,港股恒生指数跌0.63%,跌163点,报25773点;恒生科技指数跌1.27%。港股早盘成交1158亿港元。药明康德司法取得进展,有利于CXO公司在海外争取新的订单。再鼎医药涨超5%,Q2产品收入环比增长11%,花旗看好中国业务下半年企稳。津上机床中国涨超5%,电子与AI液冷两大领域在新订单占比约四成。黄金股普遍承压。油价走高加剧通胀上行担忧,美联储鹰派释放强硬信号。中国黄金国际跌2.5%;紫金矿业跌3.5%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0868486357.SGD","LU1769817096.USD","LU0737861772.HKD","LU0082770016.SGD","LU2097828714.EUR","BK1183","LU1719994722.HKD","ZIJMY","LU0326950275.SGD","LU1282648689.USD","LU2097828805.USD","BK1583","HK0000306685.HKD","LU1064131342.USD","LU1831875114.USD","BK1141","LU1481107354.HKD","LU1504937902.USD","LU0287142896.SGD","83115","06951","LU0278937759.USD","HHImain","LU0307460666.USD","LU0329678170.USD","LU0329678337.USD","LU0456854461.SGD","LU0269904917.USD","BK1594","LU0164939612.USD","LU0417516902.SGD","LU0165289439.USD","SG9999002463.SGD","LU1048596156.SGD","06616","HK0000306701.USD","LU0164880469.USD","LU0211977185.USD","LU0797268264.HKD","07300","07500","HSI","LU0328353924.USD","LU0039217434.USD","03037","09088","BK1544","02099","LU0140636845.USD","LU0370786039.SGD","LU1720050803.USD","LU0345780521.USD","LU0096374516.USD","09115","03033","LU0469268626.HKD","BK1191","LU0048580855.USD","BK1169","LU0348816934.USD","01548","LU0588546209.SGD","LU0821914370.USD","09688","BK1592","LU0049853897.USD","07226","LU0149721374.USD","LU0463099449.HKD","LU0043850808.USD","BK1109","LU0828237510.HKD","HK0000320223.HKD","LU0082770016.USD","BK1588","LU2008162690.USD","688062","LU0918141705.HKD","LU0266512473.USD","BK1587","02899","LU1808992512.USD","LU3063872942.SGD","LU2097828631.EUR","513600","300408","01541","02026","BK1574","02631","02837","PONY","JINFF","07200","LU0509642566.USD","601899","LU0540923850.HKD","LU0348767384.USD","LU0417516738.SGD","HK0000320264.USD","BK1576","LU0871576103.HKD","02833","LU2039709279.SGD","09067","LU0620787316.HKD","02800","01651","03423","LU0561508036.HKD","LU2399975544.HKD","LU2460026573.USD","LU1242518931.SGD","BK1170","LU0244354667.USD","LU1242518857.USD","LU0918141887.USD","03759","BK1198","LU2097828557.USD","BK1505","LU0061477393.USD","LU1303224171.USD","02493","LU1961090484.USD","LU0348735423.USD","LU1794554557.SGD","LU0348827113.USD","03417","LU0979878070.USD","002821","LU0886674414.USD","LU1188198961.HKD","LU0266512127.USD","LU1770034418.SGD","ZLAB","LU2264538146.SGD","LU0348766576.USD","07552","LU1251922891.USD","BK1129","LU0106252389.USD","SG9999001093.SGD","LU0106959298.USD","LU0173614495.USD","LU0431992006.USD","LU2226246903.HKD","SG9999004220.SGD","LU0634319403.HKD","LU0345780281.USD","LU0828237940.HKD","IE0032431581.USD","LU0181495838.USD","LU0348814723.USD","03088","03032","LU0228659784.USD","LU0274383008.USD","LU1224709979.USD","LU2097828474.EUR","300759","LU0164865239.USD","82800","LU0737861699.HKD","HSTECH","SG9999003461.SGD","03115","LU0828238088.HKD","LU2488822045.USD","06821","LU0531971595.HKD","MCHmain","LU1105468828.SGD","688234","LU0327786744.USD","03067","LU1988902786.USD","LU0572944931.SGD","BK1190","LU1769817179.HKD","BK1161","LU2177674079.SGD","03419","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658966444","title":"港股异动 | 再鼎医药(09688)涨超7% Q2产品收入环比增长11% 花旗看好中国业务下半年企稳","url":"https://stock-news.laohu8.com/highlight/detail?id=2658966444","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658966444?lang=zh_cn&edition=full","pubTime":"2026-08-11 10:56","pubTimestamp":1786416987,"startTime":"0","endTime":"0","summary":"消息面上,再鼎医药近日公布2026年第二季度财务业绩以及近期产品亮点和公司进展。财报显示,2026年第二季度公司总收入为1.063亿美元,产品收入净额为1.058亿美元,环比增长11%,得益于则乐的稳定表现以及艾加莫德的销量持续增长。花旗发表报告指,再鼎医药第二季产品收入按季改善约11%至约1.06亿美元,符合该行和市场预期,令该行更有信心其中国业务可于2026年下半年企稳,并按管理层指引于2027年恢复显著增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4548","LU2488822045.USD","LU0162691827.USD","BK4207","BK4531","BK4559","BK4588","LU0648001328.SGD","LU0072461881.USD","LU2360032135.SGD","LU1162221912.USD","BK1161","LU1506573853.SGD","BK4534","09688","BK4504","BK4585","LU1201861249.SGD","LU1366192091.USD","LU1791807156.HKD","FTXO","ZLAB","LU1244550221.USD","LU0203347892.USD","KCAI","IYF","LU0980610538.SGD","LU1244550577.SGD","BK4526","LU0106831901.USD","LU1668664300.SGD","LU0314106906.USD","LU2456880835.USD","LU0170899867.USD","LU1244550494.USD","LU0130102774.USD","LU0477156953.USD","LU2462157665.USD","LU0320765646.SGD","BK1588","TFNS","IE00BSNM7G36.USD","LU0130517989.USD","LU1074936037.SGD","LU2125154935.USD","LU0128525689.USD","LU2417539215.USD","LU2125154778.USD","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658963017","title":"快讯:恒指高开0.24% 科指涨0.27% 黄金股普涨 AI应用股活跃","url":"https://stock-news.laohu8.com/highlight/detail?id=2658963017","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658963017?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:20","pubTimestamp":1786411200,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端美股周一走势下滑,市场继续关注中东局势变化以及最新通胀数据表现,大市欠缺方向,三大指数均录得温和跌幅收市。美元反复向好,美国十年期债息上升至4.7厘水平,金价持续向上,油价亦表现向好。今日港股三大指数集体高开,恒指开盘涨0.24%,报25998.59点,恒科指涨0.27%,国企指数涨0.37%。盘面上,科网股涨跌不一,阿里巴巴涨超2%,小米跌近1%;AI应用股活跃,MINIMAX涨超4%;生物医药股高开,再鼎医药涨超4%;煤炭股多数上涨,中煤能源涨超1%;黄金股普涨,赤峰黄金涨超2%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-11/doc-inimwyqt7669414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BABO","LU0979878070.USD","LU2257852520.SGD","03417","IE00BF5LJ272.USD","03067","09988","02837","LU0531971595.HKD","LU2294711473.HKD","BK1615","IE0032431581.USD","BK4531","BABU","07588","LU1808992512.USD","LU0164872284.USD","LU1794554557.SGD","MIUmain","LU0823426480.USD","LU0594300419.USD","09088","LU0359201885.HKD","LU1823568750.SGD","BK4558","BK4614","BK1589","LU0651946864.USD","BK4543","IE00BFMHRM44.USD","LU0072913022.USD","LU1323998911.USD","LU0823397103.USD","LU0345775950.USD","LU0605514214.HKD","LU1267930227.SGD","BK1574","LU0345776255.USD","LU0572944931.SGD","LU0823039010.USD","LU1046422090.SGD","LU2097828714.EUR","ALBmain","ZLAB","LU0128525689.USD","LU0540923850.HKD","BK1193","BK4587","LU2148611432.USD","HK0000165453.HKD","HK0000286598.CNH","KBAB","LU1720050803.USD","LU2039709279.SGD","03423","09067","BK4534","BK1618","07226","LU0143863198.USD","BK4502","BK4535","SG9999002463.SGD","LU1769817179.HKD","LU1328277881.USD","BK1607","LU1023057109.AUD","LU2476274308.USD","LU0949170772.SGD","LU0051755006.USD","LU0456827905.SGD","LU0254981946.USD","LU0708995583.HKD","LU0054450605.USD","LU0348825331.USD","BK4579","LU0117841782.USD","HSTECH","BK1161","BK1506","LU0314109678.HKD","LU1008478684.HKD","LU1769817096.USD","LU1770036033.HKD","LU2097828474.EUR","LU0738911758.USD","BABW","BK1610","CLIX","LU0047713382.USD","LU0164865239.USD","LU2097828631.EUR","SG9999001093.SGD","LU0561508036.HKD","LU0149721374.USD","SG9999003461.SGD","03088","LU0251143458.SGD","LU0594300179.USD","LU0823041008.USD","07552","IE00B3M56506.USD","LU2097828805.USD","03032","LU0348816934.USD","LU2097828557.USD","LU0348827113.USD","LU0456842615.SGD","LU0106959298.USD","BK4526","LU1303224171.USD","BK4554","BK1575","BBYY","LU2488822045.USD","BK4503","LU1868838027.USD","BABX","LU0531970944.HKD","LU1051768304.USD","LU0463099449.HKD","LU0456846285.SGD","LU1188198961.HKD","BK1502","LU0052750758.USD","LU1813983027.USD","02828","LU0214875030.USD","HSCEI","LU1688375341.USD","BK4607","LU0307460666.USD","LU1880383366.USD","DRGN","LU1242518857.USD","ONLN","LU0169518387.USD","LU1251922891.USD","LU0231483743.USD","BK4505","BK4533","LU1242518931.SGD","09688","BK4538","LU0918141887.USD","LU1961090484.USD","LU0327786744.USD","LU0320764599.SGD","LU1105468828.SGD","LU0072462343.USD","LU0871576103.HKD","LU0650527681.SGD","LU0545039389.USD","LU0823426308.USD","HSI","LU0164880469.USD","LU0348735423.USD","LU1048596156.SGD","LU0417516902.SGD","BK4585","LU0821914370.USD","LU1051769294.HKD","LU2152927971.USD","LU2087589342.USD","LU0211977185.USD","LU1046421795.USD","LU0918141705.HKD","IE00B0JY6N72.USD","LU0039217434.USD","LU0417516738.SGD","LU0244354667.USD","LU0823040885.USD","LU1515016050.SGD","BK4524","LU0328353924.USD","LU0611395673.USD","LU1770034418.SGD","LU0880133367.SGD","07288","LU0210526637.USD","LU0499858438.USD","LU0661504455.SGD","LU0348814723.USD","BK1523","LU0310800965.SGD","LU2226246903.HKD","BK4575","LU1481107354.HKD","LU2399975544.HKD","LU1956131251.USD","LU0326950275.SGD","LU0441854154.USD","HXXD.SI","LU1235294995.USD","LU1719994722.HKD","BK4504","BK4527","LU0084288322.USD","LU0143863784.USD","81810","LU2476274720.SGD","LU0593848301.USD","LU1048588211.SGD","LU0359202008.SGD","BK4220","BK4122","XIACY","LU0052756011.USD","LU1003077747.HKD","LU0651947912.USD","LU1282648689.USD","BK4565","LU0797268264.HKD","LU1868837565.USD","LU0588546209.SGD","LU0634319403.HKD","LU0501845795.SGD","LU1152091168.USD","LU1152091754.HKD","LU1880383440.USD","01810","BABA","LU0700851271.USD","LU1981816686.USD","BK1588","LU0553294199.USD","LU0359201612.USD","LU0067412154.USD","LU0675040207.SGD","LU0823413587.USD","LU0499858602.USD","LU0823413660.USD","LU0449515922.USD","03033","82828","LU0823038988.USD","BK4548","BK4588","BK1521","LU0823397285.USD","03416","IE0034224299.USD","LU0235996351.USD","BK4581","LU0449509016.USD","DRAG","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":-0.0529},{"period":"1month","weight":0.0641},{"period":"3month","weight":0.4218},{"period":"6month","weight":0.3653},{"period":"1year","weight":-0.2036},{"period":"ytd","weight":0.4218}],"compareEarnings":[{"period":"1week","weight":-0.0036},{"period":"1month","weight":-0.0138},{"period":"3month","weight":0.0334},{"period":"6month","weight":0.1512},{"period":"1year","weight":0.1723},{"period":"ytd","weight":0.118}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再鼎医药有限公司是一家主要从事生物制药业务的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物,其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.085823},{"month":2,"riseRate":0.555556,"avgChangeRate":0.030708},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.076257},{"month":4,"riseRate":0.444444,"avgChangeRate":0.02394},{"month":5,"riseRate":0.444444,"avgChangeRate":0.004882},{"month":6,"riseRate":0.555556,"avgChangeRate":0.07528},{"month":7,"riseRate":0.444444,"avgChangeRate":0.000111},{"month":8,"riseRate":0.666667,"avgChangeRate":0.044305},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.051067},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.047464},{"month":11,"riseRate":0.555556,"avgChangeRate":0.101421},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.029495}],"exchange":"NASDAQ","name":"再鼎医药","nameEN":"Zai Lab Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,ZLAB,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}